vs
Ibotta, Inc.（IBTA）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
Ibotta, Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.2倍（$88.5M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -10.0%），Ibotta, Inc.自由现金流更多（$20.3M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 3.7%）
Ibotta, Inc.是总部位于美国科罗拉多州丹佛市的移动科技公司，成立于2011年，目前仅在美国开展业务。公司依托自主开发的Ibotta绩效网络与面向消费者的手机应用，为各类消费提供现金返现奖励，同时与快速消费品品牌及网络发行商合作，还推出了返现即服务业务。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
IBTA vs PBYI — 直观对比
营收规模更大
IBTA
是对方的1.2倍
$75.5M
营收增速更快
PBYI
高出37.7%
-10.0%
自由现金流更多
IBTA
多$5.9M
$14.4M
两年增速更快
PBYI
近两年复合增速
3.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $88.5M | $75.5M |
| 净利润 | — | — |
| 毛利率 | 78.7% | 69.3% |
| 营业利润率 | -1.9% | 22.7% |
| 净利率 | — | — |
| 营收同比 | -10.0% | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.03 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBTAPBYI
| Q4 25 | $88.5M | $75.5M | ||
| Q3 25 | $83.3M | $54.5M | ||
| Q2 25 | $86.0M | $52.4M | ||
| Q1 25 | $84.6M | $46.0M | ||
| Q4 24 | $98.4M | $59.1M | ||
| Q3 24 | $98.6M | $80.5M | ||
| Q2 24 | $87.9M | $47.1M | ||
| Q1 24 | $82.3M | $43.8M |
净利润IBTAPBYI
| Q4 25 | — | — | ||
| Q3 25 | $1.5M | $8.8M | ||
| Q2 25 | $2.5M | $5.9M | ||
| Q1 25 | $555.0K | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $17.2M | $20.3M | ||
| Q2 24 | $-34.0M | $-4.5M | ||
| Q1 24 | $9.3M | $-4.8M |
毛利率IBTAPBYI
| Q4 25 | 78.7% | 69.3% | ||
| Q3 25 | 79.4% | 77.7% | ||
| Q2 25 | 79.2% | 76.5% | ||
| Q1 25 | 79.8% | 77.1% | ||
| Q4 24 | 84.6% | 76.4% | ||
| Q3 24 | 87.7% | 63.9% | ||
| Q2 24 | 86.0% | 77.4% | ||
| Q1 24 | 87.2% | 75.5% |
营业利润率IBTAPBYI
| Q4 25 | -1.9% | 22.7% | ||
| Q3 25 | 2.8% | 17.6% | ||
| Q2 25 | 1.4% | 12.7% | ||
| Q1 25 | -3.3% | 8.7% | ||
| Q4 24 | 13.2% | 22.6% | ||
| Q3 24 | 21.0% | 27.4% | ||
| Q2 24 | -24.6% | -4.6% | ||
| Q1 24 | 19.3% | -5.3% |
净利率IBTAPBYI
| Q4 25 | — | — | ||
| Q3 25 | 1.8% | 16.2% | ||
| Q2 25 | 2.9% | 11.2% | ||
| Q1 25 | 0.7% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 17.5% | 25.2% | ||
| Q2 24 | -38.6% | -9.6% | ||
| Q1 24 | 11.3% | -11.0% |
每股收益（稀释后）IBTAPBYI
| Q4 25 | $-0.03 | $0.26 | ||
| Q3 25 | $0.05 | $0.17 | ||
| Q2 25 | $0.08 | $0.12 | ||
| Q1 25 | $0.02 | $0.06 | ||
| Q4 24 | $3.04 | $0.40 | ||
| Q3 24 | $0.51 | $0.41 | ||
| Q2 24 | $-1.32 | $-0.09 | ||
| Q1 24 | $0.33 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $186.6M | $97.5M |
| 总债务越低越好 | $0 | $22.7M |
| 股东权益账面价值 | $287.7M | $130.3M |
| 总资产 | $525.9M | $216.3M |
| 负债/权益比越低杠杆越低 | 0.00× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资IBTAPBYI
| Q4 25 | $186.6M | $97.5M | ||
| Q3 25 | $223.3M | $94.4M | ||
| Q2 25 | $250.5M | $96.0M | ||
| Q1 25 | $297.1M | $93.2M | ||
| Q4 24 | $349.3M | $101.0M | ||
| Q3 24 | $341.3M | $96.7M | ||
| Q2 24 | $317.9M | $96.8M | ||
| Q1 24 | $79.5M | $107.2M |
总债务IBTAPBYI
| Q4 25 | $0 | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $0 | $68.0M | ||
| Q3 24 | $0 | $79.3M | ||
| Q2 24 | $0 | $90.7M | ||
| Q1 24 | $65.3M | $102.0M |
股东权益IBTAPBYI
| Q4 25 | $287.7M | $130.3M | ||
| Q3 25 | $329.6M | $115.3M | ||
| Q2 25 | $354.1M | $104.7M | ||
| Q1 25 | $401.3M | $97.1M | ||
| Q4 24 | $457.3M | $92.1M | ||
| Q3 24 | $378.0M | $71.1M | ||
| Q2 24 | $359.7M | $48.5M | ||
| Q1 24 | $44.1M | $51.0M |
总资产IBTAPBYI
| Q4 25 | $525.9M | $216.3M | ||
| Q3 25 | $569.4M | $202.9M | ||
| Q2 25 | $600.8M | $194.9M | ||
| Q1 25 | $639.3M | $196.2M | ||
| Q4 24 | $678.4M | $213.3M | ||
| Q3 24 | $598.3M | $220.7M | ||
| Q2 24 | $556.0M | $205.0M | ||
| Q1 24 | $322.1M | $214.1M |
负债/权益比IBTAPBYI
| Q4 25 | 0.00× | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.00× | 0.74× | ||
| Q3 24 | 0.00× | 1.12× | ||
| Q2 24 | 0.00× | 1.87× | ||
| Q1 24 | 1.48× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.8M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $20.3M | $14.4M |
| 自由现金流率自由现金流/营收 | 22.9% | 19.1% |
| 资本支出强度资本支出/营收 | 8.5% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $75.0M | $41.7M |
8季度趋势，按日历期对齐
经营现金流IBTAPBYI
| Q4 25 | $27.8M | $14.4M | ||
| Q3 25 | $21.8M | $9.7M | ||
| Q2 25 | $25.9M | $14.1M | ||
| Q1 25 | $19.9M | $3.6M | ||
| Q4 24 | $22.0M | $15.6M | ||
| Q3 24 | $39.5M | $11.0M | ||
| Q2 24 | $35.0M | $1.0M | ||
| Q1 24 | $19.4M | $11.2M |
自由现金流IBTAPBYI
| Q4 25 | $20.3M | $14.4M | ||
| Q3 25 | $14.5M | $9.7M | ||
| Q2 25 | $22.2M | $14.1M | ||
| Q1 25 | $18.0M | $3.6M | ||
| Q4 24 | $21.8M | $15.6M | ||
| Q3 24 | $39.2M | $11.0M | ||
| Q2 24 | $34.8M | $1.0M | ||
| Q1 24 | $19.2M | — |
自由现金流率IBTAPBYI
| Q4 25 | 22.9% | 19.1% | ||
| Q3 25 | 17.4% | 17.7% | ||
| Q2 25 | 25.8% | 26.8% | ||
| Q1 25 | 21.2% | 7.7% | ||
| Q4 24 | 22.1% | 26.4% | ||
| Q3 24 | 39.8% | 13.7% | ||
| Q2 24 | 39.6% | 2.1% | ||
| Q1 24 | 23.3% | — |
资本支出强度IBTAPBYI
| Q4 25 | 8.5% | 0.0% | ||
| Q3 25 | 8.7% | 0.0% | ||
| Q2 25 | 4.2% | 0.0% | ||
| Q1 25 | 2.2% | 0.1% | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 0.2% | 0.0% | ||
| Q1 24 | 0.2% | 0.0% |
现金转化率IBTAPBYI
| Q4 25 | — | — | ||
| Q3 25 | 14.19× | 1.10× | ||
| Q2 25 | 10.38× | 2.41× | ||
| Q1 25 | 35.78× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.29× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBTA
| Redemption Revenue | $78.5M | 89% |
| Ad Other Revenue | $10.0M | 11% |
| Breakage | $2.1M | 2% |
PBYI
暂无分部数据
